REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of Two Nitrogens And Four Carbon Atoms (e.g., Pyridazines, Etc.) > 1,4-diazine As One Of The Cyclos > Piperazines (i.e., Fully Hydrogenated 1,4-diazines) > Additional Hetero Ring Attached Directly Or Indirectly To The Piperazine Ring By Nonionic Bonding Additional Hetero Ring Attached Directly Or Indirectly To The Piperazine Ring By Nonionic BondingAdditional Hetero Ring Attached Directly Or Indirectly To The Piperazine Ring By Nonionic Bonding patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.11/02/06 - 20060247249 - Carboximide derivatives as useful uro-selective alpha-1a adrenoceptor blockers Novel carboximide derivatives, which selectively inhibit binding to the α1A adrenergic receptor, a receptor which has been shown to be important in the treatment of benign prostatic hyperplasia. The compounds of the present invention are potentially useful in the treatment of benign prostatic hyperplasia. ... 10/26/06 - 20060241119 - Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives wherein Ar, Y, R1 and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder (“ADHD”), enhancing ... 10/26/06 - 20060241118 - Hydroxamate sulfonamides as cd23 shedding inhibitors A class of piperazine and related heterocyclic derivatives, substituted at the 4-position by a substituted aryl or heteroaryl moiety, and at the 1-position by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, being potent ... 10/19/06 - 20060235024 - Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists wherein R1, R2, R3, R4, M, and n are as defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy. ... 10/05/06 - 20060223814 - Nk-2 antagonist basic linear compounds and formulations containing them The present invention describes compounds with formula (I) having linear structure basic properties useful as NK-2 antagonists; pharmaceutical compositions containing said compounds are also described and processes for their preparation. ... 10/05/06 - 20060223813 - Piperazine derivatives and methods of use The invention provides 2-carboxamide piperazine compounds of formula I, R3. I N\′ N˜′ R2I(0)z- o R4 I wherein R′, R2, R3 and R4 are as defined in the claims and methods of treatment and pharmaceutical compositions that utilize or comprise one or more such compounds. Compounds of the invention are ... 08/24/06 - 20060189623 - Inhibitors of c-fms kinase wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast ... 08/10/06 - 20060178370 - Ketopiperazine derivatives as bradykinin antagonists Ketopiperazine derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. ... 08/03/06 - 20060173015 - Cyclohexyldiamines as selective alpha 1a/1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms or a pharmaceutically acceptable form thereof, as dual selective α1a/α1d adrenoreceptor antagonists for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms. The present invention also relates to pharmaceutical compositions comprising said new compounds, new processes to prepare these new compounds and new uses as a medicine as ... 07/27/06 - 20060167004 - 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders Compounds of general formula: wherein R1 and R2 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain. ... 07/13/06 - 20060154933 - Inhibitors of cdc25 phosphatases wherein the substituents are defined as in the specification. ... 07/06/06 - 20060148812 - Inhibitors of c-fms kinase wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast ... 06/29/06 - 20060142296 - 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders Compounds of general formula:[Chemical formula should be inserted here. Please see paper copy] wherein R1, R2, and R3 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain. ... 05/18/06 - 20060106025 - Dna-pk inhibitors and if Q is —NH—C(═O)—, —Y—X may additionally be selected from C1-7 alkyl. ... 04/20/06 - 20060084658 - Nitrogen-containing cyclic compound and pharmaceutical composition containing the compound In the formula, Ar indicates an optionally substituted 5- to 14-membered aromatic ring etc.; the ring A indicates any one ring selected from a piperazine, a homopiperazine, a piperidine and the like; the ring B indicates an optionally substituted C3-14 hydrocarbon ring etc.; E indicates a single bond, a group ... 02/23/06 - 20060040948 - Macrocyclic beta-secretase inhibitors R1, R2, R3, n and X are as defined in the specification. Also disclosed are pharmaceutical compositions comprising the compounds of formula I. Also disclosed are methods of treating cognitive or neurodegenerative diseases such as Alzheimer's disease. Also disclosed are methods of treating a cognitive or neurodegenerative disease comprising administering ... 01/12/06 - 20060009463 - N-(3-rifamycinyl)-carbamates, method of preparing them and their use for treating and preventing tuberculosis The present invention relates to novel N-(3-rifamycinyl)-derivatives, namely N-(3-rifamycinyl)-carbamates, methods of their preparation and their use for the production of pharmaceutical preparations. The invention also concerns a composition and a method for treating or preventing mycobacterial infections, especially tuberculosis. Formula (I); ... 01/05/06 - 20060004016 - Enantiomerically pure opioid diarylmethylpiperazine as a cardioprotection agent (−)3-((S)-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)(3-thienyl)methyl)phenol and pharmaceutically acceptable esters or salts thereof, in essentially enantiomerically pure form have utility as a therapeutic agent for mediating analgesia and treating cardiac disorders, alcohol addiction, drug overdose, cough, lung edema, diarrhea, respiratory, and gastro-intestinal disorders. ... 12/22/05 - 20050282817 - Arylpiperazines having activity at the serotonin 1a receptor A series of aryl piperazine compounds are effective pharmaceuticals for the treatment of conditions related to or affected by the serotonin 1A receptor; the compounds are particularly effective antagonists at that receptor, and are particularly useful for alleviating the symptoms of nicotine and tobacco withdrawal. ... 12/01/05 - 20050267122 - Ansamycins having improved pharmacological and biological properties Ansamycins and methods of preparing and using the same are described. At least some of these ansamycins exhibit one or more of improved aqueous formulation ability, chemical stability, and bioavailability. Some of the derivatives described are dimers. These and others described can include one or more solubilizing groups that have ... 11/17/05 - 20050256128 - Antimycobacterial pharmaceutical composition and an amount of one or more first line antitubercular drugs. ... 11/10/05 - 20050250786 - Pna monomer and precursor wherein E is nitrogen or C—R′; J is sulfur or oxygen; R′, R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrite, alkoxy, halogenated alkyl, halogenated alkoxy, phenyl or halogenated phenyl, R5 is H or protected or unprotected side chain of natural or unnatural α-amino acid; and B is ... 11/10/05 - 20050250785 - Pna monomer and precursor wherein E is nitrogen or C—R′; J is sulfur or oxygen; R′, R1, R2, R3, R4 is independently H, halogen, alkyl, nitro, nitrile, alkoxy, halogenated alkyl, halogenated alkoxy, phenyl or halogenated phenyl, R5 is H or protected or unprotected side chain of natural or unnatural α-amino acid; and B is ... 11/10/05 - 20050250784 - Inhibitors of histone deacetylase Disclosed are compounds which inhibit histone deacetylase (HDAC) enzymatic activity. Also disclosed are pharmaceutical compositions comprising such compounds as well as methods to treat conditions, particularly proliferative conditions, mediated at least in part by HDAC. ... 10/13/05 - 20050227991 - New heterocyclic or benzenic derivatives of lipoic acid, their preparation and their use as medicaments A subject of the invention is new heterocyclic or benzenic derivatives comprising a lateral chain derived from lipoic acid, which have an inhibitory activity on NO-synthase enzymes producing nitrogen monoxide NO and/or are agents allowing the regeneration of antioxidants or entities trapping the reactive oxygen species (ROS) and which intervene ... 09/08/05 - 20050197343 - Utilization of heteroarene carboxamide as dopamine-d3 ligands for the treatment of cns diseases The invention relates to neuroreceptor active N-[(4-phenyl-1-piperazinyl)alkyl]-substituted heteroarene carboxamide of general formula (I) and to structure analogous 2-ferrocenyl compounds of general formula (II) and the utilization thereof for the treatment of CNS diseases, for example, schizophrenia, different forms of depression, neurodegenerative disorders, sexual dysfunctions, cocaine, alcohol, opiate and nicotine addiction, ... 09/01/05 - 20050192283 - Fused-aryl and heteroaryl derivatives and methods of their use The present invention is directed to fused-aryl and heteroaryl derivatives, compositions containing these derivatives, and methods of their use for the prevention and treatment of conditions ameliorated by monoamine reuptake including, inter alia, vasomotor symptoms (VMS), sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders, ... 08/04/05 - 20050171116 - Enhancing the efficacy of tubercular drugs Alpha-tocopherol shows broad-spectrum anti-microbial activity against Mycobacterium Tuberculosis bacilli, against the rifampicin-resistant, isoniazid-resistant and multi-drug-resistant strains of M. tuberculosis, against Pseudomonas, against Staphylococci and against Escherichia coli. Further, the antimicrobial activity of known anti-tubercular pharmaceuticals can be improved by administering the anti-tubercular pharmaceutical together with α-tocopherol. ... 06/30/05 - 20050143386 - Diagnosis and management of infection caused by chlamydia The present invention provides a method of treating coronary artery disease in a patient in need thereof by administering to the patient an antichlamydial amount of a rifamycin for a duration to treat said coronary artery disease. ... ### FreshPatents.com Support |